Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: Under the agreement, Emergent BioSolutions will no longer enforce a contract that had allowed it to be the only company to develop a nasal spray version of the drug nalmefene for use as an antidote in a nasal spray. The attorney general's office said the new agreement came after it found that Adapt Pharma, which has since been bought by Rockville, Maryland-based Emergent, had the exclusive rights to sell the drug using Aptar Pharma's nasal spray technology. The drug is still in the pipeline and is not on the market, though. "Given the tragic, devastating effects of the opioid crisis, and the urgent need for additional drugs for the emergency treatment of opioid overdoses, my office will do whatever possible to ensure that there are no unnecessary impediments to the development of additional life-saving opioid overdose reversal drugs," Attorney General Letitia James said in a written statement. The agreement with James's office does not affect Narcan, a spray version of the drug naloxone now sold by Emergent. That from is popular for police, firefighters and others to use to try to revive people who are overdosing. It is not subject to an exclusivity agreement on the spray technology. Narcan retails for about $140 for two doses, but the company sells that amount to first responders for $75. More than 400,000 deaths in the U.S. since 2000 have been linked to opioids, a class of drugs that includes heroin, fentanyl, and prescription painkillers such as Vicodin and OxyContin. Companies would still need Food and Drug Administration approval before their products could be on the market. There is at least one effort to introduce a generic version of a naloxone nasal spray. Purdue Pharma, the maker of OxyContin, announced a grant in 2018 for a nonprofit drug company to develop one. ___ This story has been updated to correct that the drug at the center of the agreement is a spray version of nalmefene that is under development, not naloxone. It also clarifies that Narcan is sold to first responders for a lower-than-retail price.

Answer: Deal will let more companies make an overdose antidote spray.

Question: "U.S. Sen. Kelly Ayotte, a Republican, is again backing programs aimed at identifying mentally ill people who pose a risk for mass killings. Ayotte, saying she has strong bipartisan support, has co-sponsored a bill geared toward education, awareness and intervention relating to mental illness since the mass shootings in Newtown, Conn., in December 2012. Ayotte introduced the Mental Health First Aid Act in January 2013, which never made it past a congressional committee. However, elements of that bill went into the Mental Health Awareness and Improvement Act that was part of the gun control legislation the Senate voted down in April. Two days after a mass shooting at the Washington Navy Yard in September 2013, Ayotte and Sen. Mark Begich, D-Alaska, issued a joint statement to Senate leadership advocating programs to educate teachers in recognizing symptoms of mental health illness and how they could defuse potentially dangerous situations. Soon after, she appeared on CNN's The Lead With Jake Tapper. She said a bill that addresses mental health issues would pass the Senate easily. Ayotte said the mental health amendment that was attached to last April's gun-control legislation passed easily. However, it was not enacted because the gun bill itself lost. ""I actually think it can be taken up separately and easily passed because of the mental health provisions. It got over 90 votes in the Senate and very little gets 90 votes around here,"" Ayotte said. We wondered whether the mental health amendment really got such overwhelming support. We looked at the official roll call vote on the amendment and found that it had indeed passed by a 95-2 vote on April 18. Despite voting for the mental health amendment she co-sponsored, Ayotte later became one of 41 Republicans who voted against the gun control proposal sponsored by Sens. Joe Manchin, D-W.Va., and Pat Toomey, R-Pa., that would have expanded background checks. Five Democrats also voted against it. The mixed messages these votes sent drew sharp criticism from critics. Ayotte responded with a statement that said: ""I believe that restricting the rights of law-abiding gun owners will not prevent a deranged individual or criminal from obtaining and misusing firearms to commit violence. While steps must be taken to improve the existing background check system, I will not support the Manchin-Toomey legislation, which I believe would place unnecessary burdens on law-abiding gun owners and allow for potential overreach by the federal government into private gun sales."" Our ruling Ayotte said that mental health provisions related to mass shootings ""got over 90 votes in the Senate."" While an early version of the bill never made it out of committee, the Senate did eventually vote, 95-2, for a mental-health amendment to a gun control bill. The full bill lacked enough votes to pass and was pulled from the floor, but she is correct that the amendment did get 90 votes."

Answer: "Mental health provisions related to mass shootings ""got over 90 votes in the Senate."

Question: One new study found that heart attack survivors benefited from a medicine long used to treat gout. Several experimental drugs also showed early promise for interfering with heart-harmful genes without modifying the genes themselves in one case, with treatment just twice a year. The research was featured at an American Heart Association conference ending Monday in Philadelphia. "There's a lot of excitement" about the new gene-targeting medicines, especially because they seem to last so long, said Dr. Karol Watson, of the University of California, Los Angeles. Scientists have been exploring gene therapy altering DNA to attack the root cause of many diseases. The new drugs essentially accomplish the same thing without tampering with genes, said the University of Pennsylvania's Dr. Daniel Rader, who has consulted for some makers of these drugs. The medicines work by silencing or blocking messages that genes give to cells to make proteins that can do harm, such as allowing cholesterol to accumulate. The first few of these "RNA-interference" drugs recently were approved for other conditions, and research is also targeting heart disease. Farthest along is inclisiran, tested in 1,561 people with heart disease from clogged arteries who still had high LDL, the bad form of cholesterol, despite taking standard drugs. They were given a shot of inclisiran or a dummy drug when they joined the study, three months later and then every six months. The drug lowered LDL by 56% without serious side effects. More testing will show whether it also lowers heart attacks and other problems, not just cholesterol. Inclisiran's maker, The Medicines Company, plans to seek federal approval for it later this year. Two other RNA interference drugs aim at a different target triglycerides, another fat in the blood that's elevated in one quarter of Americans. Treatments include very low-fat diets, weight loss, fish oil and drugs, but doctors say more and better therapies are needed. Each RNA interference drug was tested at various doses in 40 people. A single shot lowered triglycerides by 30% to 67%, and the benefit lasted for at least four months. The studies were just intended to show safety; Arrowhead Pharmaceuticals is developing both drugs. Other research found new benefits from older drugs. AstraZeneca's Farxiga, originally developed to treat diabetes, also lowered the risk of heart problems in heart failure patients who did not have diabetes. Among 2,605 of such patients treated for 18 months, about 9% of those on Farxiga had worsening heart failure or heart-related death versus nearly 13% of those not given the drug. That worked out to a 27% lower risk, without extra serious side effects. Surprising benefits also were seen in a Canadian study of the decades-old gout drug. The anti-inflammatory drug colchicine sold as Colcrys, Mitigare and in generic form was tested in 4,745 people who recently had a heart attack. After about two years, colchicine users had a 23% lower risk of suffering a new heart attack, heart-related death, stroke, cardiac arrest or urgent need for an artery-opening procedure compared with a group given dummy pills. The benefit came mostly from preventing strokes and artery-opening procedures, and some heart doctors would rather have seen more difference in heart attacks and deaths. Colchicine is being tested in several other studies, and more evidence is needed before using it routinely to lower heart risks, Dr. L. Kristin Newby of Duke University wrote in a commentary published with the study in the New England Journal of Medicine. Dr. Donald Lloyd-Jones, a Northwestern University cardiologist and program chief for the heart conference, was more supportive. "When you have a safe drug that's easily available, it's going to be hard to hold this one back," he said. ___ Marilynn Marchione can be followed on Twitter at http://twitter.com/MMarchioneAP ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

Answer:
New, old drugs may offer fresh ways to fight heart disease.